期刊文献+

糖尿病足感染临床药物治疗的进展 被引量:1

Recent Advances of Clinical Treatment of Diabetic Foot Infections
下载PDF
导出
摘要 糖尿病足部感染是糖尿病的常见并发症,诊治轻症感染患者可选用对葡萄球菌、链球菌有活性的窄谱抗感染药物;对慢性、中重度感染或接受抗感染药物治疗无效的患者,经验性治疗应选用广谱抗感染药物。综述抗糖尿病足感染的常规治疗、重症治疗用药,以及治疗其新药研发的进展。 Diabetic foot infections are a serious complication of diabetes mellitus. Antibiotic therapy for initial mild infections can often choose those against Staphylococci and Streptococci. Empiric therapy for infections that are chronic, moderate or severe, as well as that occur in patients who have failed in previous antibiotic treatment, should usually choose the antibiotics of more broad spectrum. The author reviewed the potential role of standard and newer an- tibiotics that may be appropriate for treating diabetic foot infections, and also the advances in the new drugs clinical re- search.
出处 《抗感染药学》 2012年第3期172-176,共5页 Anti-infection Pharmacy
关键词 糖尿病足 感染性疾病 抗生素治疗 diabetic foot infections antibiotic treatment
  • 相关文献

参考文献23

  • 1Kosinski MA, Lipsky BA.Current medical management of diabetic foot infections[J]. Expert Rev Anti Infect Ther, 2010,8(11 ) 1293-305.
  • 2Bader MS, Brooks A.Medical management of diabetic foot infections[J]. Postgrad Med,2012,124(2) 102-13.
  • 3Yilmaz G,Aydin K,Iskender S,et al. Detection and preva- lence of inducible clindamycin resistance in staphylococci [J]. J Med Microbiol,2007,56(3 )342-345.
  • 4Varaiya AY,Dogra JD,Kulkarni MH,et al. Extended-spec- trum [3-1actamase-producing Escherichia coli and Klebsi- ella pneumoniae in diabetic foot infections[J]. Indian J Pathol Microbiol,2008,51( 3 ) 3 70-3 72.
  • 5Cunha BA. Oral and 1V to PO switch antibiotic therapy of hospitalized patients with serious infections[J].ScandJln- fect Dis,2008,40(11-12) 1004-1006.
  • 6Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections [J]. Lancet,2005,366(9498) 1695-1703.
  • 7Graves SF, Kobayashi SD,Deleo FR. Community-associ- ated methicillin-resistant Staphylococcus aureus immune evasion and virulence[J]. J Mol Med,2010,88(2) 109- 114.
  • 8Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomy- cin therapeutic guidelines[J].Clin Infect Dis, 2009, 49(3) 325-327.
  • 9Hazlewood KA, Brouse SD, Pitcher WD, et al. Vancomy- cin-associated nephrotoxicity:grave concern or death by character assassination[J].Am J Med, 2010, 123(2) 182, el-e7.
  • 10Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with ti- gecycline and rifampicin against Staphyloccoccus aureus [J]. J Antimierob Chemother,2009 ,63( 3 )485-488.

同被引文献11

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部